Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated condition where inflammation damages the myelin sheath around peripheral nerves. Symptoms often develop slowly over at ...

Background and Aims: Neuropathy in association with chronic liver disease, including cirrhosis, is recognized; however, there are differences in the incidence and type of neuropathy reported. The ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic or ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) treatment aims to slow immune-driven demyelination and reduce inflammation. This can help protect nerve signaling and function. First-line CIDP ...

What is the recommended approach to managing a patient infected with hepatitis C virus who has been on combination interferon and ribavirin therapy and who has developed peripheral neuropathy?

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Takeda Pharmaceutical’s Hyqvia, coformulated with Halozyme's Enhanze drug delivery ...

Half of patients referred to a specialist centre with a diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) do not actually have the condition, report researchers. Of 58 patients ...

CIDP is a treatable condition that affects the peripheral nervous system. IVIG, plasma exchange, and corticosteroid therapy are the first-line treatment options, but a newer medication for adults has ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) affects the peripheral nerves. Tests to diagnose this condition include nerve conduction studies, electromyography, and sometimes an MRI. CIDP ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired neurological disorder with heterogeneous presentation. It is a peripheral nerve system immune-mediated condition which ...